Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8305501 | 0.87 | HSD17B10 (0.50) | HSD17B10KMT2AMEN1TP53ALDH1A1 | |
| SCHEMBL8305486 | 0.83 | HSD17B10 (0.45) | HSD17B10KMT2AMEN1TP53ALDH1A1 | |
| SCHEMBL4298970 | 0.82 | HSD17B10 (0.47) | HSD17B10KMT2AMEN1FFAR1FFAR4 | |
| SCHEMBL8270290 | 0.81 | HSD17B10 (0.50) | HSD17B10KMT2AMEN1TP53ALDH1A1 | |
| SCHEMBL19049642 | 0.80 | HSD17B10 (0.43) | HSD17B10TP53FFAR1FFAR4HTR1A | |
| SCHEMBL18997973 | 0.80 | HSD17B10 (0.43) | HSD17B10FFAR1FFAR4HTR1AADRA1B | |
| SCHEMBL2760313 | 0.80 | HSD17B10 (0.57) | HSD17B10KMT2AMEN1TP53ALDH1A1 | |
| SCHEMBL17244485 | 0.79 | HSD17B10 (0.64) | HSD17B10KMT2AMEN1TP53ALDH1A1 | |
| SCHEMBL8560632 | 0.77 | HSD17B10 (0.46) | HSD17B10KMT2AMEN1TP53ALDH1A1 | |
| SCHEMBL22864649 | 0.77 | HSD17B10 (0.54) | HSD17B10KMT2AMEN1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | HSD17B10 2117/4885KMT2A 3181/4885MEN1 3536/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | HSD17B10 2132/4885KMT2A 3544/4885MEN1 4080/4885 |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | HSD17B10 3613/4885KMT2A 4024/4885MEN1 1612/4885 |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HSD17B10 3613/4885KMT2A 4024/4885MEN1 1612/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | HSD17B10 2132/4885KMT2A 3544/4885MEN1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.